Trial Profile
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Dec 2023
Price :
$35
*
At a glance
- Drugs Margetuximab (Primary) ; Tebotelimab (Primary)
- Indications Advanced breast cancer; Carcinoma; Diffuse large B cell lymphoma; Gastric cancer; Haematological malignancies; HER2 positive breast cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors MacroGenics
- 24 Mar 2023 Status changed from active, no longer recruiting to completed.
- 15 Jun 2022 Planned End Date changed from 1 Jun 2023 to 1 Feb 2023.
- 15 Jun 2022 Planned primary completion date changed from 1 Mar 2023 to 1 Feb 2023.